- SPACs
- FS Development Corp.
FS Development Corp.
Completed 2021-02-05- CIK 1816736
- FSDC
- Now GMTX
- IPO 2020-08-13
- $121M trust
- 757 filings
Successfully merged with Gemini Therapeutics, Inc. • Now trading as GMTX
- IPO Size
- $121M
- raised at the IPO
- Trust
- $121M
- as of 2020-12-31
- Current Status
- Completed
- from its latest filing
- IPO Year
- 2020
- year it listed
Filings, by quarter
757 filings over 25 quarters; violet bars carry a milestone
- 20 Q3: 21 filings
- 20 Q4: 16 filings
- 21 Q1: 55 filings
- 21 Q2: 26 filings
- 21 Q3: 9 filings
- 21 Q4: 18 filings
- 22 Q1: 27 filings
- 22 Q2: 6 filings
- 22 Q3: 7 filings
- 22 Q4: 31 filings
- 23 Q1: 65 filings
- 23 Q2: 34 filings
- 23 Q3: 23 filings
- 23 Q4: 46 filings
- 24 Q1: 37 filings
- 24 Q2: 29 filings
- 24 Q3: 12 filings
- 24 Q4: 29 filings
- 25 Q1: 41 filings
- 25 Q2: 24 filings
- 25 Q3: 42 filings
- 25 Q4: 66 filings
- 26 Q1: 34 filings
- 26 Q2: 28 filings
- 26 Q3: 31 filings
- S-1 filed 20 Q3
- IPO 20 Q3
- Definitive agreement 20 Q4
- Completed 21 Q1
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
- Registration2020-07-02 Filed S1
- IPO2020-08-13 IPO, search begins
- Definitive Agreement2020-10-15 Agreement for merger
- Completed2021-02-05 Merger Completed
About
FS Development Corp. is a blank-check company formed to effect a merger, acquisition, or similar business combination. It intends to capitalize on its management’s background and experience to identify opportunities in the biotechnology sector, with a primary focus on U.S. healthcare.
Investment Focus
Biopharmaceuticals
Geographic Focus
United States
Key Information
As the filings state it
- IPO Date
- 2020-08-13
- Total Redemptions
- $1.1K
- PIPE
- $95.1M
- SIC
- 6770
- Completion Date
- 2021-02-05
- Merger Target
- Gemini Therapeutics, Inc.
- SPAC Ticker
- FSDC
- Merged Ticker
- GMTX
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
The team includes Foresite Capital co-founder Jim Tananbaum, healthcare and life-sciences investors and executives, and experienced leaders in biotechnology, healthcare investment banking, and drug development. Foresite Capital reports a substantial biotechnology investment and financing history.